PTH and Hypocalcemia: Given that hypocalcemia is due to a secreted pro-hormone with much reduced biological activity rather than PTH-resistance, it is conceivable that patients with homozygous mutation of either amino acid residue S1 or R25 would benefit from continuous treatment with PTH(1-34) or a long-acting PTH analog (31, –33).